| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/01/2009 | EP2074117A2 Heteromonocyclic compound and use thereof |
| 07/01/2009 | EP2074115A1 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors |
| 07/01/2009 | EP2074114A1 Pyrimidinones as casein kinase ii (ck2) modulators |
| 07/01/2009 | EP2074113A1 Indazolyl derivatives useful as potassium channel modulating agents |
| 07/01/2009 | EP2074112A1 Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| 07/01/2009 | EP2074111A2 Quinolone carboxylic acids, derivatives thereof, processes for its preparation and its use as antibacterial agents |
| 07/01/2009 | EP2074108A1 Renin inhibitors |
| 07/01/2009 | EP2074107A2 Tricyclic compounds as matrix metalloproteinase inhibitors |
| 07/01/2009 | EP2074106A1 Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| 07/01/2009 | EP2074105A1 Cyclopropyl-piperazine compounds as calcium channel blockers |
| 07/01/2009 | EP2074103A1 6-phenylpyrimidinones as pim modulators |
| 07/01/2009 | EP2074102A1 2-phenyl indene derivatives useful as estrogen receptor ligands |
| 07/01/2009 | EP2074100A1 Biofilm-inhibiting effect and anti-infective activity of n,c-linked arylisoquinolines and the use thereof |
| 07/01/2009 | EP2074099A1 Quinolinone derivatives |
| 07/01/2009 | EP2074098A2 Quinoline compounds |
| 07/01/2009 | EP2074097A2 Compounds for treating proliferative disorders |
| 07/01/2009 | EP2074096A1 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
| 07/01/2009 | EP2074094A1 Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists |
| 07/01/2009 | EP2074093A2 Matrix metalloproteinase inhibitors |
| 07/01/2009 | EP2074092A2 Inhibitors of d-amino acid oxidase |
| 07/01/2009 | EP2074091A1 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
| 07/01/2009 | EP2074090A1 Vinylogous acids derivatives as chymase inhibitors |
| 07/01/2009 | EP2074088A2 N-substituted-azacyclylamines as histamine-3 antagonists |
| 07/01/2009 | EP2074087A2 Synthesis of pyrrolidine compounds |
| 07/01/2009 | EP2074086A1 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| 07/01/2009 | EP2074085A2 Anti-infective thiourea compounds |
| 07/01/2009 | EP2074084A1 Compounds which modulate the cb2 receptor |
| 07/01/2009 | EP2074083A1 New sulfonamide derivatives as bradykinin antagonists |
| 07/01/2009 | EP2074082A1 Polymorphs of o-desmethyl venlafaxine succinate |
| 07/01/2009 | EP2073899A1 The use of a dna damaging agent and a ligand for the treatment of cancer |
| 07/01/2009 | EP2073898A1 Complement inhibition for improved nerve regeneration |
| 07/01/2009 | EP2073847A2 Methods and materials for reducing risk of cold and/or flu |
| 07/01/2009 | EP2073837A2 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer |
| 07/01/2009 | EP2073820A2 Targeted polymeric prodrugs containing multifunctional linkers |
| 07/01/2009 | EP2073818A2 Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors |
| 07/01/2009 | EP2073817A1 Medicagenic acid saponin and uses thereof |
| 07/01/2009 | EP2073816A2 Inhibitors of fatty acid amide hydrolase |
| 07/01/2009 | EP2073815A1 Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof |
| 07/01/2009 | EP2073814A2 Novel method of treatment of male sub-fertility |
| 07/01/2009 | EP2073813A2 Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
| 07/01/2009 | EP2073812A2 Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism |
| 07/01/2009 | EP2073810A2 Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile compound for treating diabetes, cancer, autoimmune disorders and hiv infection |
| 07/01/2009 | EP2073809A2 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 07/01/2009 | EP2073808A2 New method for the treatment of inflammatory diseases |
| 07/01/2009 | EP2073807A1 Pharmaceutical combinations |
| 07/01/2009 | EP2073806A2 Use of spiro-oxindole compounds as therapeutic agents |
| 07/01/2009 | EP2073805A1 Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 07/01/2009 | EP2073804A2 Hydroxy-substituted benzoic acid amide compounds for use in therapy |
| 07/01/2009 | EP2073803A1 Pharmaceutical combinations |
| 07/01/2009 | EP2073802A1 Pharmaceutical combinations |
| 07/01/2009 | EP2073801A1 Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| 07/01/2009 | EP2073800A2 Ophthalmic compositions comprising diglycine |
| 07/01/2009 | EP2073799A2 Novel agents of calcium ion channel modulators |
| 07/01/2009 | EP2073798A2 Pharmaceutical nimodipine compositions |
| 07/01/2009 | EP2073797A2 Pharmaceutical compositions |
| 07/01/2009 | EP2073796A1 Pharmaceutical formulation comprising metformin and repaglinide |
| 07/01/2009 | EP2073795A1 Abuse resistant drug formulation |
| 07/01/2009 | EP2073793A2 Compositions containing coenzyme q-10 in reduced form and dihydrolipoic acid |
| 07/01/2009 | EP2073792A2 Superporous hydrogels |
| 07/01/2009 | EP2073790A1 Particle formation |
| 07/01/2009 | EP2073637A1 Compounds useful for treating neurodegenerative disorders |
| 07/01/2009 | EP2073636A1 Process for preparing oxymorphone |
| 07/01/2009 | EP2073635A1 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/01/2009 | EP2073634A1 Stabilized prostaglandin e composition |
| 07/01/2009 | EP2037941A4 Cobalamin compositions and methods for treating or preventing mucositis |
| 07/01/2009 | EP2007384B1 Orodispersible domperidone tablets |
| 07/01/2009 | EP2005948A9 Perfluorocarbon gas transferring emulsion for medico-biological use, the composition and the production method thereof a medicinal agent |
| 07/01/2009 | EP2005945A9 Oseltamivir phosphate granule and preparation mehtod thereof |
| 07/01/2009 | EP1883407A4 Compositions and methods for treatment for neoplasms |
| 07/01/2009 | EP1868999B1 Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| 07/01/2009 | EP1861365B1 N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| 07/01/2009 | EP1858852B1 Heteroarylsulfonyl stilbenes as 5-ht2a antagonists |
| 07/01/2009 | EP1850837B1 Use of morpholino compounds for the prevention of bacterial contamination |
| 07/01/2009 | EP1838710B1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| 07/01/2009 | EP1833308B1 Increasing the protein concentration of animal organisms |
| 07/01/2009 | EP1784393B1 Quinazolines useful as modulators of ion channels |
| 07/01/2009 | EP1784173A4 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives |
| 07/01/2009 | EP1756043B1 Ortho substituted aryl or heteroaryl amide compounds |
| 07/01/2009 | EP1747221B1 Fused ring nk1 antagonists |
| 07/01/2009 | EP1747006B1 Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug |
| 07/01/2009 | EP1740583B1 Oxadiazolone derivatives as ppar delta agonists |
| 07/01/2009 | EP1740576B1 Novel piperidine substituted diaminothiazoles |
| 07/01/2009 | EP1713439B1 Pharmaceutical preparation for the oral cavity |
| 07/01/2009 | EP1697343B1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| 07/01/2009 | EP1694314A4 Treatment and preventions of asthma |
| 07/01/2009 | EP1691810A4 Substituted piperazines |
| 07/01/2009 | EP1686999B1 Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| 07/01/2009 | EP1684770B1 Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer |
| 07/01/2009 | EP1682126B1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 07/01/2009 | EP1651230B1 Medicaments for inhalation comprising steroids and a novel fluorene carboxylic acid ester |
| 07/01/2009 | EP1646612B1 Processes for preparing montelukast sodium |
| 07/01/2009 | EP1644350B1 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors |
| 07/01/2009 | EP1613296B1 Methods for treatment of parkinson's disease |
| 07/01/2009 | EP1611104B1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| 07/01/2009 | EP1599455B1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
| 07/01/2009 | EP1576159B1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 07/01/2009 | EP1552018B1 Methods and compositions relating to gene silencing |
| 07/01/2009 | EP1537075B1 Diarylurea derivatives and their use as chloride channel blockers |
| 07/01/2009 | EP1529116B1 Method for predicting the responsiveness to treatment with rivastigmine based on the ApoE genotyp of dementia patients |
| 07/01/2009 | EP1511721B1 Guanidino phenylalanin compounds used as urokinase inhibitors |